Bright Comet G3 ATLAS Expected to Dazzle Skywatchers This Month

US
Published:

Astronomers are eagerly anticipating the arrival of Comet G3 ATLAS, which is predicted to become the brightest comet seen in nearly two decades. The comet, first discovered on April 5, 2024, is expected to achieve peak brilliance from January 12 to 14, 2025, as it passes perilously close to the sun.

Initially classified as a new comet from the distant Oort cloud, further observations revealed G3 ATLAS to be an ancient voyager, having an orbital period of approximately 160,000 years. As it approaches perihelion on January 13, the comet is expected to illuminate the night sky, potentially reaching a brightness comparable to that of Venus, with predictions of a magnitude between -3 and -6.

Southern Hemisphere observers have had the best views of G3 ATLAS so far, as its trajectory has mainly traversed southern constellations like Scorpius and Sagittarius. However, as the comet shifts position in the coming days, there will be opportunities for viewers in the Northern Hemisphere to catch a glimpse, especially around sunrise and sunset on January 12 and 14, respectively.

Recent observations noted an unexpected brightness surge, with some experts uncertain about the comet’s stability. Observers are advised to use binoculars for the best chance of spotting G3 ATLAS, which may only appear as a bright star.

For safety when attempting to view the comet at its brightest near January 13, astronomers caution against daytime observations, as looking directly at the sun poses health risks.

With its potential brilliance, G3 ATLAS is set to become a significant event in the astronomical calendar for 2025, captivating stargazers worldwide.

Weekly Newsletter

News summary by melangenews

Loading...

More from United States

Tragic Collision of Passenger Plane and Military Helicopter in Washington Claims 67 Lives

A catastrophic midair collision between a passenger plane and a military helicopter in Washington D.C. on Wednesday resulted in the deaths of all 67 individuals on board. The incident involved American Airlines flight 5342, which was a Bombardier CRJ-700 carrying 60 passengers and four crew members, and a military Sikorsky H-60 Black Hawk helicopter occupied by three service members. The collision occurred over the Potomac River at approximately 8:48 PM local time while the plane was making its final approach to Ronald Reagan Airport. Eyewitness reports indicated that the helicopter veered dangerously close to the aircraft before the impact, causing both to explode in midair. Emergency teams recovered 28 bodies from the plane and one from the helicopter, confirming that no survivors emerged from the wreckage. American Airlines expressed its condolences and stated that it is cooperating with investigation efforts, while President Donald Trump commented on the tragedy, stating it "seemed avoidable" given the clear weather conditions and routine approach procedure. A joint investigation by civil and military authorities is underway to determine the accident's cause.
US

FDA Approves Revolutionary Bioengineered Blood Vessel for Trauma Treatments

The U.S. Food and Drug Administration (FDA) has approved a groundbreaking bioengineered blood vessel aimed at addressing the needs of trauma patients. Developed by North Carolina-based Humacyte, this vessel is designed to integrate with a patient’s body over time, providing a solution for individuals who have suffered severe injuries that impede blood circulation, particularly in cases of amputation. According to founder and CEO Laura Niklason, traditional treatments using veins are often inadequate, especially when patients cannot provide usable options from their own bodies. The FDA approval follows extensive testing involving 51 civilian and 16 military patients, revealing that nearly 92% of the engineered vessels remained functional after 30 days, compared to 79% for synthetic alternatives. Additionally, the infection rate for the bioengineered vessels was under 1%, significantly lower than the over 8% rate associated with synthetic grafts, as published in the journal JAMA Surgery. While the approved application is limited to trauma cases, Humacyte is exploring additional uses for its technology, including potential applications in kidney dialysis and peripheral artery disease.
US

Trump Plans to Detain 30,000 Migrants at Guantanamo Bay

Former President Donald Trump has outlined a controversial plan to detain up to 30,000 migrants at the Guantanamo Bay detention facility if he is re-elected in 2024. According to a statement released by Trump's campaign, this measure aims to address illegal immigration and bolster national security. This proposal comes amidst intensifying discussions on immigration policies in the United States, reflecting Trump's previously embraced hardline stance during his presidency. Trump's administration was marked by strict immigration measures, including family separations and the construction of barriers along the U.S.-Mexico border. Critics of the plan have raised concerns about humanitarian implications and the legality of detaining a large number of migrants indefinitely. Legal experts argue that such actions could face significant pushback in courts. The proposal reflects a broader trend among certain political leaders advocating for stringent immigration control as a response to increasing cross-border migration. As the 2024 presidential election approaches, Trump's immigration policy is expected to be a focal point of debate among candidates.
US